Skip to main content
TipRanks
Go Ultimate75% OFF

Oaktree Specialty Lending (OCSL) Q4 2026 Earnings Report

922 Followers

OCSL Q4 2026 EPS Results

Actual EPS
$0.34
Consensus EPS
$0.34
Beat/Miss
Beat by +$0.00
One Year Ago EPS
$0.41

OCSL Q4 2026 Revenue Results

Actual Revenue
$56.15M
Expected Revenue
$69.97M
Beat/Miss
Missed by -$13.82M
YoY Revenue Growth
-33.36%

Earnings Announcement Details

Quarter
Q4 2026
Date
11/17/2026
Time
Before Open
Conference Call
Tuesday, November 17, 2026
OCSL Upcoming Earnings

Oaktree Specialty Lending's next earnings date is estimated for February 4, 2027, based on past reporting schedules.

Q4 2026 Earnings Call Audio

OCSL Q4 2026 Earnings Call
0:00 / 0:00

Q4 2026 Earnings Slide Deck

Q4 2026 Earnings Call Summary

Q4 2026
Earnings Call Date:Nov 17, 2026|% Change Since:-2.58%|
Earnings Call Sentiment|Positive

The call was broadly constructive, supported by a 44% reduction in non-accrual dollars, successful credit resolutions, strong liquidity, conservative leverage, a stable ratings outlook, and a well-diversified portfolio positioned for higher rates. However, adjusted net investment income and total investment income declined both sequentially and year over year, NAV decreased, originations remained below prior-year levels, and several non-accruals and market challenges persisted. Highlights outweighed the lowlights, but the outlook remains dependent on continued credit resolutions and portfolio deployment.

Company Guidance

For fiscal 2027, OCSL’s top priorities are unchanged: resolve non-accruals, exit non-income-producing equity positions and redeploy those proceeds into performing assets; with net leverage of 1.00x and nearly $700 million of pro forma liquidity, the company has flexibility to be opportunistic, and it is comfortable taking leverage up within its target range of 0.9x to 1.25x, having run leverage between 0.97 and 1.07 in 2026. Beginning in the December quarter, the September rate hike will start to flow through to net investment income, with the majority of the impact expected in December quarter earnings and the full effect building from there; once fully reset, every 25 basis point increase in base rates adds a little over $0.05 per share per quarter to adjusted net investment income with a little over $0.02 per share annualized. BioXcel’s additional $67.5 million milestone is expected to be paid within 30 days.

  • Non-Accruals Declined MateriallyNon-accruals fell to approximately 1.8% of the total debt portfolio at fair value, down about 120 basis points year over year and relatively unchanged from June. Non-accrual dollars declined from $81 million to $45 million, a 44% reduction, with nearly 85% of the decline resulting from proceeds received and investments returning to accrual status.
  • Improved Credit ResolutionsBayMark came off non-accrual after lenders recapitalized and stabilized the business. Thrasio's remaining balance was fully paid down at par in early November. The company also expects a relatively quick resolution for BioXcel Therapeutics; following Teva's FDA approval for BioXcel's drug, a $67.5 million milestone payment to lenders was triggered and is expected within 30 days, leading to realized value well in excess of OCSL's carrying mark.
  • Successful RumbleOn ExitOCSL's remaining $35 million first lien position in RumbleOn was repaid at 101, including an exit fee, one year ahead of the 2027 maturity. Management said its structured loan, covenant resets, maturity extension, and collaborative turnaround plan helped produce a positive outcome.
  • Strong Balance Sheet FlexibilityMoody's revised OCSL's outlook to stable while maintaining its Baa3 rating. The company priced $300 million of five-year unsecured notes due 2031 at a 7% coupon and 240 basis points over U.S. Treasuries; the final order book exceeded three times the deal size and included new OCSL bond investors. Net leverage ended at 1.00x, within the 0.9x to 1.25x target range, and pro forma liquidity was approximately $689 million.
  • Staggered Debt Maturities and High Unsecured Debt MixAfter the January 2027 notes are repaid using the revolving credit facility, the next debt maturity will be February 2029. Unsecured debt represented approximately 88% of total debt at quarter end and approximately 64% pro forma for repayment of the 2027 notes.
  • Floating-Rate Portfolio Positioned for Higher RatesApproximately 91% of debt investments are floating rate and 100% of debt is floating or swapped to floating. Management stated that a move in short-term base rates from approximately 4% to 5% would remain manageable and could benefit investor returns. Weighted average interest coverage was 2.3x and would be approximately 2.1x after a 100-basis-point increase in base rates.
  • Potential Earnings Benefit From Rate HikeThe September rate hike is expected to begin flowing through net investment income in the December quarter, with the majority of the impact expected in that quarter and the full effect building thereafter. Management stated that, once fully reset, every 25-basis-point increase in base rates adds a little over $0.05 per share per quarter to adjusted net investment income.
  • New Originations Offered Attractive PricingNew investment commitments totaled $179 million during the quarter, with weighted average yield on new debt investments of 9.6% and new-origination spreads of approximately 570 basis points, wider than the market range of 500 to 550 basis points. OCSL originated approximately $80 million of new commitments in October as its pipeline built steadily since late September.
  • Notable Outcomes First Group InvestmentOCSL anchored a first lien loan to Outcomes First Group, the U.K.'s largest independent provider of schools for children and youth with special educational needs and disabilities. The GBP 600 million facility was priced at SONIA plus 525 basis points with 1.5 points of OID and supported refinancing and further expansion.
  • Portfolio Diversification and Credit QualityThe portfolio included 170 companies, with no single position exceeding 2.1% of total portfolio fair value. Approximately 79.1% of the portfolio at fair value was first lien senior secured debt. Weighted average portfolio leverage was 5.1x and interest coverage was 2.3x, both steady sequentially and year over year.
  • Reduced Software and AI-Related ConcentrationSoftware represented 20% of the portfolio at fair value, down from 24% a year ago. Approximately 94% of software positions were first lien, ARR-based loans represented only 0.8% of the portfolio, and high-AI-risk software exposure remained approximately 3% of performing debt.
  • Dividend Maintained With Supplemental DistributionThe Board declared a total quarterly cash dividend of $0.32 per share, consisting of a $0.30 base dividend and a $0.02 supplemental dividend. Fiscal 2026 dividends totaled $1.39 per share, and the supplemental dividend remained equal to 50% of adjusted net investment income above the base dividend.
  • Income-Producing Equity Investments AddedOCSL participated in three performing equity investments during the quarter, increasing equity exposure to 5.5% of fair value from 3.9% in the prior quarter. Management described these investments as highly structured, with negotiated downside protection and income-producing characteristics.
  • Joint Ventures Generated Positive ReturnsThe joint ventures held approximately $547 million of investments across 144 portfolio companies and generated aggregate returns on equity of approximately 11.5% during the quarter. JV leverage improved to 2.0x from 2.1x.

OCSL Earnings History

OCSL earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Feb 04, 20272027 (Q1)0.32-0.42――
Nov 17, 20262026 (Q4)0.340.340.41-17.07% (-0.07)
Aug 05, 20262026 (Q3)0.360.370.38-2.63% (-0.01)
May 05, 20262026 (Q2)0.370.390.45-13.33% (-0.06)
Feb 04, 20262026 (Q1)0.380.420.54-22.22% (-0.12)
Nov 18, 20252025 (Q4)0.390.410.55-25.45% (-0.14)
Aug 05, 20252025 (Q3)0.450.380.54-29.63% (-0.16)
May 01, 20252025 (Q2)0.510.450.56-19.64% (-0.11)
Feb 04, 20252025 (Q1)0.530.540.57-5.26% (-0.03)
Nov 19, 20242024 (Q4)0.560.550.62-11.29% (-0.07)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed